drugset
drugset / Trial / NCT05380271

Efficacy and Safety of DEB-BACE With Sequential Arotinib and Tirelizumab in the Treatment of Advanced NSCLC

NCT05380271 ↗

Phase 2 Unknown 60 enrolled Gang Wu
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, open-labelled study to evaluate the efficacy and safety of arterial infusion chemotherapy combined with drug loaded microspheres embolization with sequential arotinib and tirelizumab in the treatment of advanced NSCLC. The progression-free-survival (PFS) will be evaluated as the primary endpoints.

Timeline

Start
2022-07-01
Primary completion
2022-12-01
Completion
2025-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Arotinib Unknown 8 mg Oral
Subject Arotinib Unknown 12 mg Oral
Subject Tirelizumab Monoclonal antibody 200 mg Intravenous
Comparator Letitrexed Unknown 3 mg/m2 Other
Comparator Nedaplatin Small molecule 40 mg/m2 Other
Background THP Unknown 20 mg/m2 Other
Comparator THP Unknown 20 mg/m2 Other
Background THP Unknown 30 mg/m2 Other
Comparator THP Unknown 30 mg/m2 Other
Background THP Unknown 40 mg/m2 Other
Comparator THP Unknown 40 mg/m2 Other
Background THP Unknown 600 mg/m2 Other
Comparator THP Unknown 600 mg/m2 Other

Indications

non-small cell lung carcinoma